Gilmore Neil O'Neill sold $15k of EDIT
CEO at Editas Medicine, Inc.. 5,592 shares at an average of $2.60, traded Sep 3, 2025, filed Sep 4, 2025.
Score components
- +25RoleCEO
- 0Trade size$15k at market
- 0Share of holdings soldSold 2.0% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +55.6%, 3m -3.6%, 6m -24.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001650664-25-000141, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -5,592 | $2.60 | $15k | 274,690 | Sep 4, 2025 |
Related signals
Other insiders at Editas Medicine, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | Editas Medicine, Inc. | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | $2,153 709 shares | -1% | |
| 20Weak | Editas Medicine, Inc. | Gilmore Neil O'Neill CEO | $16k 5,124 shares | -2% | |
| 17Weak | Editas Medicine, Inc. | Amy Parison SVP, Chief Financial Officer | $1,376 453 shares | -3% | |
| 10Weak | Editas Medicine, Inc. | Amy Parison SVP, Chief Financial Officer | $1,749 678 shares | -5% | |
| 3Weak | Editas Medicine, Inc. | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | $13k 4,928 shares | -7% | |
| 10Weak | Editas Medicine, Inc. | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | $1,975 731 shares | -1% | |
| 26Weak | Editas Medicine, Inc. | Gilmore Neil O'Neill CEO | $42k 15,380 shares | -6% | |
| 17Weak | Editas Medicine, Inc. | Amy Parison SVP, Chief Financial Officer | $1,253 464 shares | -3% | |
| 10Weak | Editas Medicine, Inc. | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | $1,513 749 shares | -1% | |
| 17Weak | Editas Medicine, Inc. | Amy Parison SVP, Chief Financial Officer | $957 474 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.